FDA approves Lundbeck’s Vyepti™ (eptinezumab-jjmr) – the first and only intravenous preventive treatment for migraine
We are now scheduling appointments for Vyepti Infusions! This is the first intravenous (IV) treatment for migraine prevention and the latest in a new class of monoclonal antibodies used for the preventive treatment of migraine.
Eptinezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor. The drug is expected to launch commercially in April of 2020 and should be administered every three (3) months via a 30-minute IV infusion.
This is yet another very exciting development for people living with migraine.
Call The Manhattan Center for Headache & Neurology to schedule your very first Vyepti Infusion. Schedule a telehealth consult or an in person consult to determine if VYEPTI infusion therapy is right for you. Let us help you lead a pain free life!
Our center follows all rules and regulations to maintain a sanitized facility to ensure that you continue to be safe and healthy during this COVID-19 health crisis.